Basic Information
Fluidda is the world leader in Functional Respiratory Imaging (FRI). This technology combines HRCT scans with Computational Fluid Dynamics (CFD) to offer significant improvements by making clinical trials shorter, faster, and more cost-effective. FRI also provides a unique entry point for personalized medicine by optimizing diagnosis, monitoring disease progression, and evaluating treatment effects, including accurate assessment of inhaled drug deposition, benefiting both patients and healthcare providers. Fluidda’s mission is to optimize treatment pathways, reduce healthcare costs, and shorten the time-to-market for respiratory drugs, pulmonary medical devices, and treatment methods. Fluidda has offices in Belgium, the United States (New York and Los Angeles), and Portugal (Lisbon).